Consensus estimates for Johnson & Johnson's third quarter of 2026 call for revenue of $25.40 billion and adjusted EPS of $2.66, as the stock trades near $261.44 against an average analyst target of $276.09.
Investors are primarily focused on the deepening revenue erosion of the blockbuster immunology drug Stelara following its loss of patent exclusivity and the resulting impact on long-term pharmaceutical growth.
Despite these headwinds, analysts anticipate growth to be supported by strong performance in oncology drug sales and the ramp-up of new product launches like the psoriasis treatment Icotyde. Meanwhile, the MedTech division remains under scrutiny for signs of recovery in procedure volumes and its resilience against competitive pricing pressures in the Chinese market.